NCT00001082 - The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients | Biotech Hunter

Enrollment

505

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

January 31, 1999

Study Completion Date

August 31, 1999

Conditions

Cytomegalovirus InfectionsHIV Infections

Interventions

DRUG

Levocarnitine

500 mg tablet taken orally daily

DRUG

Adefovir dipivoxil

120 mg tablet taken orally daily

DRUG

Adefovir dipivoxil placebo

Oral placebo tablet taken daily

Trial Locations (15)

10037

Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York

19107

Philadelphia FIGHT, Philadelphia

20422

Washington Reg AIDS Prog / Dept of Infect Dis, Washington D.C.

23298

Richmond AIDS Consortium / Div of Infect Diseases, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Wayne State Univ - WSU/DMC / Univ Hlth Ctr, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

80204

Denver CPCRA / Denver Public Hlth, Denver

87131

Partners in Research / New Mexico, Albuquerque

94110

Community Consortium / UCSF, San Francisco

97210

The Research and Education Group, Portland

08103

Southern New Jersey AIDS Cln Trials / Dept of Med, Camden

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH